Literature DB >> 11501989

Investigational antifungal agents.

E J Ernst1.   

Abstract

Several new antifungal agents, including novel compounds in familiar classes and entirely new classes targeting previously untapped mechanisms, are in various stages of the drug development process. Many new triazole antifungal agents are being studied, including voriconazole, posaconazole, and ravuconazole. The echinocandin antifungals, which represent a new class of antifungal agents, possess activity against a variety of fungal pathogens. The sodarin derivatives and nikkomycins are two additional classes of antifungals in early stages of development; future studies will determine their therapeutic usefulness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11501989     DOI: 10.1592/phco.21.12.165s.34509

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.

Authors:  Andreja Hasenoehrl; Tatjana Galic; Gabrijela Ergovic; Natasa Marsic; Mihael Skerlev; Joachim Mittendorf; Ulrich Geschke; Axel Schmidt; Wolfgang Schoenfeld
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism.

Authors:  Peter M Silver; Brian G Oliver; Theodore C White
Journal:  Eukaryot Cell       Date:  2004-12

4.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 5.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

6.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 7.  Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Authors:  Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

8.  Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.

Authors:  Robert S Liao; Robert P Rennie; James A Talbot
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 9.  Invasive aspergillosis in children with hematologic malignancies.

Authors:  Rashed A Hasan; Walid Abuhammour
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 10.  Invasive oesophageal candidiasis: current and developing treatment options.

Authors:  Jose A Vazquez
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.